PHVS

Pharvaris N.V.

Price

$38.02

return (12m)

63.88%

p/e

-13.72

p/bv

7.22

DIVIDEND YIELD

0.00%

PHVS price

Pharvaris

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PHVS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

7.55%

3 months

20.55%

1 year

63.88%

2 years

81.74%

5 years

118.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals PHVS

Valuation

P/E

-13.72

Sector -3.82

Industry -3.82

P/BV

7.22

Sector 2.08

Industry 2.08

P/Revenue (PSR)

Sector 2.04

Industry 2.04

EV/EBITDA

-36.65

Sector -226.01

Industry -226.01

EV/EBIT

-36.52

Sector -49.26

Industry -49.26

P/EBITDA

-11.84

Sector -21.23

Industry -21.23

P/EBIT

-11.81

Sector -31.44

Industry -31.44

P/Total Assets

6.61

Sector 1.22

Industry 1.22

P/Net Current Assets

7.27

Sector -10.53

Industry -10.53

P/Working Capital

6.65

Sector -172.76

Industry -172.76

EPS

-2.81

Sector -1.85

Industry -1.85

BVPS

5.33

Sector 2.00

Industry 2.00

Efficiency

Gross Margin

0.00%

Sector 40.67%

Industry 40.67%

EBITDA Margin

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

0.00%

Sector -35.88%

Industry -35.88%

Net Profit Margins

0.00%

Sector -36.71%

Industry -36.71%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-52.66%

Sector -58.37%

Industry -58.37%

ROA

-48.19%

Sector -61.30%

Industry -61.30%

ROIC

-2,113.18%

Sector -2,355.96%

Industry -2,355.96%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

1,696.35

Sector 2.88

Industry 2.88

Net Debt / EBITDA

6.29

Sector -14,081,727.47

Industry -14,081,727.47

Net Debt / EBIT

6.27

Sector -8.03

Industry -8.03

Net Debt / Equity

-1.06

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

0.92

Sector 0.45

Industry 0.45

Liabilities/Assets

0.08

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

39.23%

Sector -

Industry -

Fundamentals PHVS

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PHVS Pharvaris N.V.	$38.02	63.88%	0.00%	-13.72	7.22	-52.66%	0.00%
JNJ Johnson & Johnson	$265.58	52.53%	1.98%	30.47	7.54	24.76%	21.48%
PFE Pfizer Inc.	$27.72	24.31%	6.24%	35.93	1.84	5.11%	6.86%
ABBV AbbVie Inc.	$257.12	21.52%	2.65%	72.22	-76.87	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.07	-17.59%	4.32%	10.50	5.58	53.11%	35.32%
MRK Merck & Co. Inc.	$143.93	80.59%	2.33%	112.32	8.48	7.55%	4.76%
AZN AstraZeneca PLC	$160.17	2.40%	2.03%	19.00	4.89	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$63.64	44.28%	3.96%	13.95	5.80	41.55%	18.85%
ZTS Zoetis Inc.	$72.97	-49.82%	2.89%	11.41	9.59	84.02%	27.77%
AMGN Amgen Inc.	$377.35	40.29%	2.25%	26.93	20.14	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$781.49	40.10%	0.47%	18.62	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$107.20	39.40%	0.00%	30.46	87.77	288.13%	24.86%
MCK McKesson Corporation	$881.51	24.54%	0.37%	19.68	-26.99	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$515.44	30.65%	0.00%	29.63	6.45	21.76%	35.00%
CAH Cardinal Health Inc.	$234.57	56.04%	0.88%	31.71	-20.07	-63.29%	0.68%
ARGX argenx SE	$984.39	30.14%	0.00%	2.61	3.00	114.60%	44.55%
HRMY Harmony Biosciences Holdings Inc.	$41.52	28.19%	0.00%	13.26	2.41	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PHVS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Pharvaris

Pharvaris N.V.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2021

Time since IPO - 5 years

148

Employees

Pharvaris N.V. (United States) is listed on the Nasdaq and has a market capitalization of $2.50 billion, with shareholders equity totaling $346.56 million.

The company employs approximately 148 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Pharvaris N.V. reported $- in revenue, generating net income of $-182.48 million.

Key financial metrics include a P/E ratio of -13.72, a price-to-book (P/B) ratio of 7.22, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PHVS.

Market cap

$2.50 billion

Net worth

$346.56 million

$346,556,000.00

Assets

$378.65 million

$378,649,000.00

Total Shares Outstanding

65.00 million

65,000,000

Average Daily Trading Volume

$719.94 Thousand

$719,944.50

Sector

Health Care

Industry

Biotechnology

PHVS

PHVS revenue and profits

Financial Results PHVS

DRAG THE FRAME TO SEE MORE DATA

PHVS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$881.51 24,54% (12M)

P/E

19.68

0.37%

ROE

-137.16%

P/BV

-26.99

CAH - Cardinal Health

$234.57 56,04% (12M)

P/E

31.71

0.88%

ROE

-63.29%

P/BV

-20.07

JNJ - Johnson & Johnson

$265.58 52,53% (12M)

P/E

30.47

1.98%

ROE

24.76%

P/BV

7.54

ABBV - AbbVie

$257.12 21,52% (12M)

P/E

72.22

2.65%

ROE

-106.44%

P/BV

-76.87

MRK - Merck & Co.

$143.93 80,59% (12M)

P/E

112.32

2.33%

ROE

7.55%

P/BV

8.48

AZN - AstraZeneca

$160.17 4,38% (12M)

P/E

19.00

2.03%

ROE

25.77%

P/BV

4.89

PFE - Pfizer

$27.72 24,31% (12M)

P/E

35.93

6.24%

ROE

5.11%

P/BV

1.84

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$881.51 24,54% (12 M)

P/L

19.68

0.37%

ROE

-137.16%

P/VP

-26.99

CAH - Cardinal Health

$234.57 56,04% (12 M)

P/L

31.71

0.88%

ROE

-63.29%

P/VP

-20.07

JNJ - Johnson & Johnson

$265.58 52,53% (12 M)

P/L

30.47

1.98%

ROE

24.76%

P/VP

7.54

ABBV - AbbVie

$257.12 21,52% (12 M)

P/L

72.22

2.65%

ROE

-106.44%

P/VP

-76.87

MRK - Merck & Co.

$143.93 80,59% (12 M)

P/L

112.32

2.33%

ROE

7.55%

P/VP

8.48

AZN - AstraZeneca

$160.17 4,38% (12 M)

P/L

19.00

2.03%

ROE

25.77%

P/VP

4.89

PFE - Pfizer

$27.72 24,31% (12 M)

P/L

35.93

6.24%

ROE

5.11%

P/VP

1.84

Frequently Asked Questions

What is the price of Pharvaris (PHVS) today?

A cotação de Pharvaris (PHVS) hoje está em US$ 38.02, com uma variação de 63.88% em relação ao último ano. A cotação de Pharvaris (PHVS) iniciou o ano negociando na casa dos US$ 27.75 e hoje está em US$ 38.02. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Pharvaris (PHVS) e dados de ações do Ibovespa e mercados internacionais.

Quando Pharvaris (PHVS) paga dividendos?

Pharvaris (PHVS) não distribuiu dividendos no último ano.

Is Pharvaris (PHVS) a good investment?

Atualmente, Pharvaris (PHVS) está cotada a US$ 38.02, com um P/L de -13.72, representando um desvio de -989% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 63.88 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 63.88%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Pharvaris (PHVS) stock?

Investir em ações de Pharvaris (PHVS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Pharvaris (PHVS) yield today?

A rentabilidade de Pharvaris (PHVS) foi de 7.55% no último mês, 63.88% no último ano e 118.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Pharvaris (PHVS) hoje, o investimento total seria de US$ 3,802.00, com base na cotação atual de US$ 38.02.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 6,230.72
Em 5 anos: US$ 8,288.36
Em 10 anos: US$ 3,802.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PHVS

Pharvaris N.V.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PHVS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING PHVS WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Pharvaris

Pharvaris N.V.

United States

11 years

2021

148

PROFIT X PRICE PHVS

Financial Results PHVS

PHVS cash flow

Asset, Revenue and Profit Growth - PHVS

PHVS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions